Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

Please scroll down for information on Junior Investigator Transthyretin Amyloid Polyneuropathy (ATTR-PN) Research

Request for Proposals (RFP)

Junior Investigator Transthyretin Amyloid Polyneuropathy (ATTR-PN) Research

Date RFP Issued: January 15, 2021

Geographic Scope: all countries except the United States

Clinical Area: Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Link to full RFP: Junior Investigator Transthyretin Amyloid Polyneuropathy (ATTR-PN) Research

Application Due Date: March 22, 2021

Specific Area of Interest: Pfizer is interested in supporting research proposals that advance our understanding of the epidemiology, basic science and early diagnosis and treatment of ATTR-PN through research focused in the following areas:

  • Epidemiologic evaluations for ATTR-PN
  • Approaches for the early appropriate diagnosis of ATTR-PN patients
  • Evaluation of patients with ATTR-PN presenting with a mixed phenotype
  • Real world efficacy and safety of tafamidis monotherapy in the clinical setting for the management of ATTR-PN
  • Mechanistic studies to advance the basic science of amyloid formation and deposition 

Refer to complete details in the full RFP documents. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).